Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.78 |
---|---|
High | 5.99 |
Low | 5.60 |
Bid | 5.90 |
Offer | 5.91 |
Previous close | 5.75 |
Average volume | 10.58m |
---|---|
Shares outstanding | 286.64m |
Free float | 267.01m |
P/E (TTM) | -- |
Market cap | 1.65bn USD |
EPS (TTM) | -1.53 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 17:15 GMT.
More ▼
- Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
- Recursion and Exscientia Shareholders Approve the Proposed Combination
- Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
- Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
- Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
- Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
- Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
- Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
- CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
- Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
More ▼